<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Retrovirology</journal-id><journal-title>Retrovirology</journal-title><issn pub-type="epub">1742-4690</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1742-4690-3-90</article-id><article-id pub-id-type="pmid">17144914</article-id><article-id pub-id-type="doi">10.1186/1742-4690-3-90</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Gallo</surname><given-names>Stephen A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sgallo@aibs.org</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Reeves</surname><given-names>Jacqueline D</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>jreeves@MonogramBio.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Garg</surname><given-names>Himanshu</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>gargh@ncifcrf.gov</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Foley</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>btf@lanl.gov</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Doms</surname><given-names>Robert W</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>doms@mail.med.upenn.edu</email></contrib><contrib id="A6" corresp="yes" contrib-type="author"><name><surname>Blumenthal</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>blumen@helix.nih.gov</email></contrib></contrib-group><aff id="I1"><label>1</label>Center for Cancer Research Nanobiology Program, National Cancer Institute at Frederick, National Institutes of Health, Frederick, MD, USA</aff><aff id="I2"><label>2</label>Dept. Microbiology, University of Pennsylvania, Philadelphia, PA, USA</aff><aff id="I3"><label>3</label>Los Alamos National Laboratories, Los Alamos, NM, USA</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>4</day><month>12</month><year>2006</year></pub-date><volume>3</volume><fpage>90</fpage><lpage>90</lpage><ext-link ext-link-type="uri" xlink:href="http://www.retrovirology.com/content/3/1/90"/><history><date date-type="received"><day>13</day><month>7</month><year>2006</year></date><date date-type="accepted"><day>4</day><month>12</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Gallo et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Gallo et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Gallo A Stephen sgallo@aibs.org </dc:author><dc:title> Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>Retrovirology 3(1): 90-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1742-4690(2006)3:1&#x0003c;90&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1742-4690</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>HIV envelope glycoprotein (Env)-mediated fusion is driven by the concerted coalescence of the HIV gp41 N-helical and C-helical regions, which results in the formation of 6 helix bundles. Kinetics of HIV Env-mediated fusion is an important determinant of sensitivity to entry inhibitors and antibodies. However, the parameters that govern the HIV Env fusion cascade have yet to be fully elucidated. We address this issue by comparing the kinetics HIV-1<sub>IIIB </sub>Env with those mediated by HIV-2 from two strains with different affinities for CD4 and CXCR4.</p></sec><sec><title>Results</title><p>HIV-1 and HIV-2 Env-mediated cell fusion occurred with half times of about 60 and 30 min, respectively. Binding experiments of soluble HIV gp120 proteins to CD4 and co-receptor did not correlate with the differences in kinetics of fusion mediated by the three different HIV Envs. However, escape from inhibition by reagents that block gp120-CD4 binding, CD4-induced CXCR4 binding and 6-helix bundle formation, respectively, indicated large difference between HIV-1 and HIV-2 envelope glycoproteins in their CD4-induced rates of engagement with CXCR4.</p></sec><sec><title>Conclusion</title><p>The HIV-2 Env proteins studied here exhibited a significantly reduced window of time between the engagement of gp120 with CD4 and exposure of the CXCR4 binding site on gp120 as compared with HIV-1<sub>IIIB </sub>Env. The efficiency with which HIV-2 Env undergoes this CD4-induced conformational change is the major cause of the relatively rapid rate of HIV-2 Env mediated-fusion.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The origins of Human Immunodeficiency Virus (HIV) can be traced to zoonotic transmissions of Simian Immunodeficiency Virus (SIV) to humans from at least two different kinds of non-human primates [<xref ref-type="bibr" rid="B1">1</xref>]: HIV-1, which came from chimpanzees, and HIV-2, which came from sooty mangabeys. While similar in many ways, there are important differences between HIV-1 and HIV-2 that provide insights into virus evolution, tropism and pathogenesis [<xref ref-type="bibr" rid="B2">2</xref>]. Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection and often some degree of CD4-independence. Despite considerable sequence and phenotypic differences between HIV-1 and 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal and C-terminal regions of the ectodomain [<xref ref-type="bibr" rid="B3">3</xref>], which is common to many viral and cellular fusion proteins and which seems to drive fusion [<xref ref-type="bibr" rid="B4">4</xref>]. HIV-1<sub>IIIB </sub>gp41 helical regions can form more stable 6-helix bundles than HIV-2<sub>SBL </sub>gp41 helical regions [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>]; however HIV-2 fusion occurs at a lower threshold temperature (25&#x000b0;C), does not require Ca<sup>2+ </sup>in the medium, is insensitive to treatment of target cells with cytochalasin B [<xref ref-type="bibr" rid="B6">6</xref>], and is not affected by target membrane glycosphingolipid composition [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>In order to elucidate mechanisms of HIV envelope glycoprotein-mediated fusion we have kinetically resolved steps in the pathway of HIV-1 membrane fusion [<xref ref-type="bibr" rid="B8">8</xref>]. To gain a better understanding of the molecular mechanisms underlying these steps, we compared kinetic parameters of HIV-1<sub>IIIB </sub>with two strains of HIV-2. We found a significant difference in fusion kinetics, which appears to be related to the CD4-induced rate of engagement of HIV gp120 with its coreceptor. Since the CD4-induced binding of gp120 proteins to CXCR4 is not very different between the different strains, we surmise that in the intact Env other regions (e.g. the cytoplasmic tail) may have a profound influence on the conformational changes in the surface-exposed portions of the envelope glycoproteins.</p></sec><sec><title>Results</title><sec><title>Fusion kinetics</title><p>We examined the dye transfer that occurs as result of fusion between HeLa cells infected with recombinant vaccinia viruses expressing Env proteins and labeled with a red tracker dye and target SupT1 cells labeled with calcein at different times of co-culture at 37&#x000b0;C. Figure <xref ref-type="fig" rid="F1">1</xref> shows that once cells expressing HIV-1<sub>IIIB </sub>Env were mixed with SupT1 cells, fusion began after a lag phase at 37&#x000b0;C of about 30 min, with 50% of maximum fusion (t<sub>1/2</sub>) occurring at 63 &#x000b1; 6 min. HIV-2<sub>SBL </sub>and HIV-2<sub>ROD </sub>Env-mediated fusion, on the other hand, showed no appreciable lag time and 50% of maximum fusion was reached in 23 &#x000b1; 4 and 28 &#x000b1; 2 minutes, respectively.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Kinetics of HIV-1 and HIV-2 Env-mediated fusion</bold>. HIV-1<sub>IIIB </sub>(squares), HIV-2<sub>SBL </sub>(triangles), and HIV-2<sub>ROD </sub>(circles) Env proteins were expressed in HeLa cells using vaccinia recombinants as described in Materials and Methods. Target SupT1 cells, labeled with calcein, were added to the plated HeLa cells, labeled with CMTMR, at various times during a two hour period at 37&#x000b0;C. The cells were then examined by fluorescence microscopy for dye transfer indicating cell-cell fusion. Lines represent fits to the sigmoidal equation f = <italic>a</italic>/(1-exp [-<italic>b</italic>(<italic>t </italic>- <italic>t</italic><sub>1/2</sub>)]) using Sigmaplot (SPSS, Chicago). Values of time for half maximal fusion (t<sub>1/2</sub>) are 63 &#x000b1; 6, 28 &#x000b1; 2 and 23 &#x000b1; 4 minutes for HIV-1<sub>IIIB</sub>, HIV-2<sub>SBL </sub>and HIV-2<sub>ROD</sub>, respectively.</p></caption><graphic xlink:href="1742-4690-3-90-1"/></fig></sec><sec><title>Binding of HIV-1 and HIV-2 gp120 to CD4 and CXCR4</title><p>In previous studies we have found that fusion rates can be dependent on the affinity with which an Env binds to its coreceptor [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Potentially, differences in CD4 affinity could also impact fusion kinetics. We therefore performed studies to assess the binding of soluble gp120s derived from each of the virus strains to CXCR4 or CD4. Cells expressing no receptor (pcDNA3 transfected), CD4 or CXCR4 were incubated with equivalent amounts of purified HIV-1 or HIV-2 gp120s with or without the presence of soluble CD4 (to allow CXCR4 binding), and were then washed, lysed and assayed for binding through Western blot analysis (Figure <xref ref-type="fig" rid="F2">2</xref>). HIV-2<sub>ROD </sub>gp120 bound CD4 poorly as compared with HIV-2<sub>SBL </sub>gp120, but HIV-2<sub>ROD </sub>gp120 exhibited stronger binding to CXCR4 as compared to HIV-2<sub>SBL </sub>gp120. HIV-1<sub>IIIB </sub>gp120 was more similar to HIV-2<sub>SBL </sub>gp120 in its CD4 and CXCR4 binding profile than HIV-2<sub>ROD </sub>gp120 (Figure <xref ref-type="fig" rid="F2">2</xref>). Specificity of binding was demonstrated by sCD4 inhibition of CD4 binding and a lack of CXCR4 binding in the absence of sCD4 (data not shown).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Binding of soluble gp120 to cellular CD4 orCXCR4</bold>. Receptor binding efficiencies of gp120s were determined using a cell surface-binding assay in which bound protein was detected by Western blot analysis as described in Materials and Methods. Binding to CXCR4 was performed in the presence of sCD4 to expose the coreceptor binding site. HIV-1<sub>IIIB </sub>and HIV-2<sub>SBL </sub>gp120 exhibited relatively high CD4 binding efficiencies but weak CXCR4 binding. HIV-2<sub>ROD </sub>gp120 exhibited relatively weak binding to CD4 and relatively high binding to CXCR4. Numbers indicate mean band intensity following subtraction of background pcDNA3 lane intensity.</p></caption><graphic xlink:href="1742-4690-3-90-2"/></fig><p>These binding data were further corroborated by inhibition studies of HIV-1 and HIV-2-mediated fusion. Dose-response curves were generated for inhibition of gp120-CD4 binding by Leu3A, and for gp120-CXCR4 binding by AMD3100. Table <xref ref-type="table" rid="T1">1</xref> shows the IC50 values derived from these curves. Higher amounts of inhibitor are required to displace ligands with high affinity for their receptor, provided that the ligands bind in a similar fashion. The high IC50 for inhibition of HIV-2<sub>ROD </sub>by AMD3100 (Table <xref ref-type="table" rid="T1">1</xref>) is entirely consistent with its binding potency shown in figure <xref ref-type="fig" rid="F2">2</xref>. HIV-1<sub>IIIB </sub>and HIV-2<sub>SBL</sub>, on the other hand, had low IC50's for inhibition by AMD3100 (Table <xref ref-type="table" rid="T1">1</xref>) consistent with low affinity for CXCR4 as suggested by the data in figure <xref ref-type="fig" rid="F2">2</xref>. The gp120-CD4 binding data shown in figure <xref ref-type="fig" rid="F2">2</xref> are also consistent with inhibition of fusion by Leu3A. HIV-2<sub>ROD </sub>showed little binding to CD4, and its IC50 for inhibition by Leu3A was the lowest compared to HIV-1<sub>IIIB </sub>and HIV-2<sub>SBL</sub>. The latter two showed binding to CD4 in the Western blot assay and had higher IC50 values. The binding of HIV-1 and HIV-2 gp120 to CD4 and CXCR4 per se does therefore not appear to account for the differences in fusion kinetics.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Inhibition of HIV-1 and HIV-2 Env-mediated fusion. AMD3100 or Leu3A were added to cocultures of HIV-expressing cells and target cells at the time of co-culture and fusion was measured as described in Methods. IC50 values were derived from dose-response by fitting the data to a hyperbolic decay function.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="2"><bold>IC50 (&#x003bc;g/ml) for fusion at 37&#x000b0;C</bold></td></tr></thead><tbody><tr><td></td><td align="left"><bold>AMD3100</bold></td><td align="left"><bold>Leu3A</bold></td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left">HIV-1<sub>IIIB</sub></td><td align="left">0.53 &#x000b1; 0.07</td><td align="left">0.3 &#x000b1; 0.1</td></tr><tr><td align="left">HIV-2<sub>ROD</sub></td><td align="left">&#x0003e;10</td><td align="left">0.03 &#x000b1; 0.02</td></tr><tr><td align="left">HIV-2<sub>SBL</sub></td><td align="left">0.14 &#x000b1; 0.02</td><td align="left">0.09 &#x000b1; 0.01</td></tr></tbody></table></table-wrap></sec><sec><title>Escape from inhibition by Leu3A and C34</title><p>In previous studies we had dissected the kinetics of HIV-1 Env-mediated fusion by adding inhibitors that act at the various steps of the fusion reaction [<xref ref-type="bibr" rid="B11">11</xref>] at different times following co-culture of Env-expressing cells with target cells. In those studies we observed a large time differential between losses of sensitivity to Leu3A as compared to AMD3100. However, loss of sensitivity to C34 occurred nearly concomitantly with loss of sensitivity to AMD3100 indicating that the HIV-1 gp41 6-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 env-mediated fusion process. In order to analyze the rate-limiting step in HIV-2<sub>SBL </sub>Env-mediated fusion we performed similar loss of sensitivity studies. Previously we had shown that SIV C34 is a good inhibitor of HIV-1 as well as HIV-2 fusion [<xref ref-type="bibr" rid="B3">3</xref>]. We used concentrations of C34 at which HIV-2<sub>SBL </sub>Env-mediated fusion was completely inhibited. Figure <xref ref-type="fig" rid="F3">3</xref> shows that the kinetics of loss of sensitivity to Leu3A, AMD3100 and C34 were indistinguishable with t<sub>1/2</sub>'s of about 27 min, indicating that the HIV-2 envelope glycoprotein assumes its CXCR4-grabbing conformation very rapidly after engagement with CD4.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Time course for escape from HIV-2</bold><sub>SBL</sub><bold>Env-mediated fusion inhibition</bold>. Fusion was measured as described in the legend to figure 1. Leu3A (3 &#x003bc;g/ml, triangles), AMD3100 (40 &#x003bc;M, circles) and SIV C34 (2 &#x003bc;M, squares) were added at different times following co-culture at 37&#x000b0;C and residual fusion was measured following their time of addition. The curves were fitted by the sigmoidal function given in the legend to figure 1; values of time for half maximal fusion (t<sub>1/2</sub>) are 26.9 &#x000b1; 4.1, 24.8 &#x000b1; 6.4 and 26.4 &#x000b1; 2.3 minutes for Leu3A (green), AMD3100 (red) and C34 (blue), respectively.</p></caption><graphic xlink:href="1742-4690-3-90-3"/></fig></sec></sec><sec><title>Discussion</title><p>The current model of HIV viral entry involves the binding of the trimeric viral Env glycoprotein gp120/gp41 to cell surface receptor CD4, which triggers conformational changes in the envelope proteins. Gp120 is then re-positioned allowing gp41 to undergo conformational changes that result in the formation of the gp41 "pre-hairpin" [<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>]. Upon engagement with chemokine co-receptors CXCR4 or CCR5 [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>], the C-terminal heptad repeat region and the leucine/isoleucine zipper region form the thermostable 6-helix bundle, which drives membrane merger and eventual fusion [<xref ref-type="bibr" rid="B17">17</xref>]. In the case of HIV-1<sub>IIIB </sub>it appears that the pre-hairpin conformation is quite a long lasting state [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. Previously, we had attributed the relatively slow kinetics of HIV-1 Env-mediated fusion to the stochastic nature of HIV Env triggering giving rise to a relatively low probability of 6-helix bundle formation and fusion [<xref ref-type="bibr" rid="B8">8</xref>]. We had invoked the "harpoon" model [<xref ref-type="bibr" rid="B15">15</xref>] according to which the HIV-1 gp120 is searching to engage its co-receptor following initial conformational changes induced by CD4 binding. We had shown that HIV-1 gp41 6-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process [<xref ref-type="bibr" rid="B11">11</xref>]. We reasoned that higher gp120-coreceptor affinities may result in more rapid gp120-coreceptor binding leading to enhanced rates of 6-helix formation and fusion. This hypothesis has been born out in studies showing that envelope:coreceptor affinity correlates with fusion kinetics [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>].</p><p>In this study we show that fusion mediated by the HIV-1<sub>IIIB </sub>Env exhibits slower kinetics as compared to that of two different HIV-2 Envs (Figure <xref ref-type="fig" rid="F1">1</xref>). Since we observed little CD4-induced binding of gp120 from HIV-1<sub>IIIB </sub>and HIV-2<sub>SBL </sub>to CXCR4 under steady-state condition (figure <xref ref-type="fig" rid="F2">2</xref>), and similar AMD3100 susceptibilities (Table <xref ref-type="table" rid="T1">1</xref>) that are in contrast to efficient CXCR4 binding and markedly reduced AMD3100 susceptibility for HIV-2<sub>ROD</sub>, the difference in fusion rates mediated by these HIV-1 and HIV-2 Envs are not likely due to differences in gp120-coreceptor affinity per se. However, the time of addition experiments (figure <xref ref-type="fig" rid="F3">3</xref>) indicate that the major difference in kinetics between HIV-1<sub>IIIB </sub>and HIV-2<sub>SBL </sub>lays in the efficiency of conformational changes that occur after CD4 is bound and that result in the formation of the coreceptor-binding site. In the case of HIV-1, exposure of the coreceptor binding site has not yet occurred immediately after the stage that Leu3A can block. It has been shown that binding of a single CD4 molecule to an envelope trimer leads to conformational changes in all three gp120 molecules [<xref ref-type="bibr" rid="B19">19</xref>]. This process may take a relatively long time in the case of HIV-1 Env. By contrast, the coreceptor binding site is rapidly exposed following CD4 binding in the case of HIV-2 Env consistent with the observation that HIV-2 strains (in contrast to HIV-1) are often able to infect cells CD4-independently. Since CD4-induced binding of soluble gp120 molecules to CXCR4 was not very different between the HIV-1<sub>IIIB </sub>and HIV-2<sub>SBL </sub>strains, we surmise that in the intact Env other regions may have a profound influence on this conformational change.</p><p>In order to examine other regions that may affect the rate of HIV Env-mediated fusion we performed a sequence comparison between HIV-1<sub>HxB2 </sub>(which is similar to HIV-1<sub>IIIB</sub>) and the two HIV-2 strains studied in this paper (figure <xref ref-type="fig" rid="F4">4</xref>). The regions considered important for fusion (fusion peptide, N-helical region, membrane proximal region and transmembrane anchor seem to be well conserved between the strains. The C-helical regions appear to be dissimilar which could account for the differences in 6-helix bundle stabilities between HIV-1<sub>IIIB </sub>and HIV-2 [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. However, the differences in gp41 refolding into 6-helix bundles in the intact envs do not correlate with 6-helix bundle stabilities of the peptides derived from those regions.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Sequence comparison of HIV-1 and HIV-2 Envs</bold>. The HIV-1 subtype B infectious molecular clone HXB2 Env gp41 sequence (Database accession number K03455) is aligned to the HIV-2 ROD (M15390) and ISY (J04498) Env gp41 sequences. Amino Acid sites conserved in all 3 sequences are shaded black, and those conserved in 2 of the 3 are shaded grey. Numbering is based on the HXB2 amino acid sequence. The sequences corresponding approximately to the different regions of HIV-1 gp41 have been highlighted as follows: Membrane Anchor (180&#x02013;203), red; Lentivirus Lytic Peptide-3 (268&#x02013;286), green; Lentivirus Lytic Peptide-2 (287&#x02013;313), cyan; Lentivirus Lytic Peptide-1 (326&#x02013;354), turquoise. Note the lack of homology in LLP-2 and 3 sequences, whereas LLP-1 (337&#x02013;354) appears to be very homologous between the three strains.</p></caption><graphic xlink:href="1742-4690-3-90-4"/></fig><p>Another region of HIV-1 gp41 that has profound effects on fusion rates is the cytoplasmic tail [<xref ref-type="bibr" rid="B20">20</xref>]. HIV-1, HIV-2 and SIV CTs are remarkably long and contain domains that likely interact with host cell components, such as calmodulin [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>], &#x003b1;-catenin [<xref ref-type="bibr" rid="B21">21</xref>], p115-RhoGEF [<xref ref-type="bibr" rid="B23">23</xref>], Prenylated Rab acceptor protein [<xref ref-type="bibr" rid="B24">24</xref>], or AP-1 clathrin adaptor proteins [<xref ref-type="bibr" rid="B25">25</xref>]. Three alpha helical "lentivirus lytic peptide" domains (LLP-1, LLP-2 and LLP-3) highly conserved in HIV-1 have been implicated in interacting with the cytoplasmic leaflet of plasma membrane, decreasing bilayer stability, altering membrane ionic permeability, and mediating cell killing [<xref ref-type="bibr" rid="B26">26</xref>-<xref ref-type="bibr" rid="B28">28</xref>]. Poorly defined regions of gp41 have also been implicated in interacting with viral matrix proteins during virion assembly [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. This interaction also modulates Env function in that gp41 is more stably associated with immature rather than mature viral particles [<xref ref-type="bibr" rid="B30">30</xref>], and cleavage of the p55 Gag precursor protein by the viral protease is required to generate Envs with maximal fusogenicity [<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>].</p><p>Truncations of gp41 proximal to the most N-terminal alpha helix, LLP-2, produced a significant increase in the rate of HIV-1 Env-mediated cell fusion [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. These effects were not seen with a truncation distal to this domain and before LLP1 [<xref ref-type="bibr" rid="B20">20</xref>]. These results were observed for X4-, R5-, and dual-tropic Envs on CXCR4- and CCR5-expressing target cells. Sequence comparisons of gp41 derived from HIV-1, HIV-2 and SIV indicate high homology between the three viral Envs in the LPP-1 region but not in the LLP-2 region of the cytoplasmic tail (the sequence comparisons can be obtained from Brian Foley upon request). In the case of certain HIV-1 Env strains it has been shown that CT truncations prior to LLP-2 profoundly affect the exposure of CD4-induced epitopes on gp120 [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B34">34</xref>], indicating that "inside-out" signalling changes the conformation in the Env ectodomain. Although we have performed this analysis by comparing only one HIV-1 and two HIV-2 strains we believe that the methodology developed here can be expanded to include comparisons between various strains of HIV-1 and HIV-2. Future studies that involve domain swapping between HIV-1 and HIV-2 gp41 CT's will determine whether our LLP-2 hypothesis turns out to be correct.</p></sec><sec><title>Conclusion</title><p>We find that the differences in fusion mediated by HIV-1 and HIV-2 Env are due to the rates by which the Envs assume a conformation that expose the binding sites on gp120 to the CXCR4 following engagement with CD4. In spite of the fact that CD4-induced binding to CXCR4 of isolated gp120 derived from HIV-1<sub>IIIB </sub>and HIV-2<sub>SBL </sub>were similar, their rate of binding to the co-receptor was markedly different in the context of the complete Envs. We speculate that sequences in the cytoplasmic tail of the Env may have a profound influence upon the rate by which the extracytoplasmic portion of gp120 assumes its CXCR4-engageable conformation.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Cells</title><p>QT6, 293T and HeLa cell lines were cultured in DMEM supplemented with 10% fetal calf serum, 60 mg/ml of penicillin and 100 mg/ml streptomycin. Sup-T1 cells (Non-Hodgkin's T-cell lymphoma cell line) were cultured in RPMI supplemented with 10% serum, 60 mg/ml of penicillin and 100 mg/ml streptomycin.</p></sec><sec><title>Inhibitors</title><p>The fusion inhibitor SIV C34 [<xref ref-type="bibr" rid="B3">3</xref>] was dissolved in PBS at a stock concentration of 500 uM. The CXCR4 antagonist AMD3100 [<xref ref-type="bibr" rid="B35">35</xref>], a kind gift from Anormed, Inc. (Langley, Canada), was dissolved in PBS at a stock concentration of 1 &#x003bc;g/ul. Leu3A, an antibody against the gp120 binding site of CD4 and a highly effective fusion inhibitor [<xref ref-type="bibr" rid="B36">36</xref>] (BD Biosciences, San Jose, CA), was dissolved in 0.1% Azide at 25 ug/ml. All inhibitors were stored at 4&#x000b0;C.</p></sec><sec><title>Plasmids</title><p>The 3' half proviral clone of HIV-2<sub>SBL </sub>(KF-3; kindly provided by G. Franchini) was used as a template for PCR amplification of the envelope gene using 5' CACCATGAGTGGTAAAATTCAGCTGC 3' and 5' CTCCTTGCTGATATCTCTGTCCCTCA 3' oligonucleotides. The PCR product was cloned into the pcDNA3.1 D/V5-His-TOPO expression vector (Invitrogen, Carlsbad, CA) to generate an sbl/isy gp160 expression construct. A stop codon was introduced at the gp120/gp41 cleavage junction of the sbl/isy gp160 expression construct using the 'Quikchange' site directed mutagenesis kit (Stratagene, La Jolla, CA) and 5' GGGAGACATAAGAGATGAAAGCTTGTGCTAGGGTTC 3' and 5' GAACCCTAGCACAAGCTTTCATCTCTTATGTCTCCC 3' oligonucleotides to generate a gp120 expression construct. These oligonucleotides also introduce an HindIII restriction enzyme site (for screening purposes) down stream of the stop codon. HIV-2<sub>ROD/A </sub>and HIV-1<sub>IIIB </sub>gp120 expression vectors have been described previously [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B38">38</xref>].</p></sec><sec><title>Vaccinia recombinants</title><p>HIV-1 and HIV-2 Env proteins were expressed in HeLa cells using the following vaccinia recombinants;vPE16, for the IIIB strain of HIV-1 [<xref ref-type="bibr" rid="B39">39</xref>], vvROD, for the ROD strain of HIV-2 [<xref ref-type="bibr" rid="B40">40</xref>], and vSC50 for the SBL/ISY strain of HIV-2 [<xref ref-type="bibr" rid="B41">41</xref>]. These recombinants were incubated with cells overnight at a ratio of 10:1 infectious virions to cells. HeLa cells were plated on 12 or 24 well plates overnight before infection (Costar, Cambridge, MA). The recombinant vTF1.1 vaccinia virus encoding T7 polymerase was used to drive expression of plasmids with the T7 promoter.</p></sec><sec><title>Cell-Cell fusion assay</title><p>For dye transfer assays [<xref ref-type="bibr" rid="B11">11</xref>], HeLa cells infected with recombinant vaccinia viruses expressing Env proteins and labeled with CMTMR (494/517, red) and target SupT1 cells labeled with Calcein (541/565, green) in suspension were co-cultured (Molecular Probes, Eugene, OR). Kinetic experiments were conducted in which target SupT1 cells in suspension in 37&#x000b0;C media were added to plated effector cells at various times during a two hour period. The cells were then examined by fluorescence microscopy for dye transfer between Env and receptor expressing cells indicating cell-cell fusion. Phase and fluorescent images were collected using an Olympus IX70 coupled to a CCD camera (Princeton Instruments, Trenton, NJ) with a 10&#x000d7; objective lens. An 82000 optical filter cube (Chroma Technology Corp., Brattleboro, VT) was used for the excitation of calcein and CMTMR. Three images per well were collected and then analyzed using Metamorph software (Universal Imaging, West Chester, PA) for dye transfer from the donor to the acceptor cell. The scoring of fusion events was conducted as previously described [<xref ref-type="bibr" rid="B18">18</xref>]. The results were normalized by the control fusion and expressed as a percentage. Curves for fusion inhibition assays were fitted, using a hyperbolic decay function, and the IC50 was extracted. Fusion kinetics curves were fit to a sigmoidal function and the half time, at which 50% fusion was achieved, was extracted.</p></sec><sec><title>Env:Receptor binding assay</title><p>gp120s were produced from 293T cells calcium phosphate transfected with gp120 expression constructs and infected with vTF1.1 vaccinia virus. Cell culture supernatants were harvested 24 hours post transfection/infection and gp120 concentrations determined by ELISA as previously described [<xref ref-type="bibr" rid="B42">42</xref>] with the exception that different antibodies were utilized. Receptor binding efficiencies of gp120s were determined using a cell surface-binding assay in which bound protein is detected by Western blot analysis [<xref ref-type="bibr" rid="B38">38</xref>,<xref ref-type="bibr" rid="B43">43</xref>]. Briefly, 2 &#x000d7; 10<sup>6 </sup>QT6 target cells were calcium phosphate transfected with 6 ug pcDNA3.1 (control), CD4 or CXCR4 expression plasmids in 25 cm<sup>2 </sup>culture flasks and infected with vTF1.1 to boost expression. 24 hrs post-transfection/infection, cells were incubated with gp120 for 2 hours at room temperature with and without 5 ug/ml soluble CD4 (sCD4) to trigger coreceptor binding site exposure. Cells were washed 3&#x000d7; with cold PBS to remove unbound gp120 then lysed with NP40 lysis buffer (0.5% NP40, 150 mM NaCl, 50 mM Tris pH 8) on ice for 10 minutes. Clarified lysates were assayed for gp120 content by SDS-PAGE and Western blotting and detected with an HIV-1 Env specific rabbit serum and an HRP-conjugated anti-rabbit antibody (Amersham Life Science, Piscataway, NJ) or a HIV-2 Env reactive MAb and an HRP-conjugated anti-mouse antibody (Promega, Madison, WI) followed by Supersignal chemiluminescent substrate (Pierce, Rockford, IL). Band intensity was quantitated using Kodak 1D software.</p></sec></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>SAG and HG performed the kinetic studies of HIV env-mediated fusion, JDR cloned and expressed HIV gp120 and performed the binding studies, BF performed the sequence alignment analysis, RWD participated in the design of the study and helped to draft the manuscript and RB conceived of the study, participated in its design and coordination and wrote the manuscript. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Aimee Kessler for technical assistance. We are grateful to the NIH AIDS Research and Reference Reagent Program for supply of Sup-T1 cells and VSC50, VVROD and VPE16 recombinants. We are grateful to AnorMED Inc. for a gift of AMD3100. We thank Geneveffa Franchini for the supply of HIV-2 envelope plasmids. We thank the members of the Blumenthal lab for their helpful suggestions. This research was supported [in part] by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Shaw</surname><given-names>GM</given-names></name><name><surname>De Cock</surname><given-names>KM</given-names></name><name><surname>Sharp</surname><given-names>PM</given-names></name></person-group><article-title>AIDS as a zoonosis: scientific and public health implications</article-title><source>Science</source><year>2000</year><volume>287</volume><fpage>607</fpage><lpage>614</lpage><pub-id pub-id-type="pmid">10649986</pub-id><pub-id pub-id-type="doi">10.1126/science.287.5453.607</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>JD</given-names></name><name><surname>Doms</surname><given-names>RW</given-names></name></person-group><article-title>Human immunodeficiency virus type 2</article-title><source>J Gen Virol</source><year>2002</year><volume>83</volume><fpage>1253</fpage><lpage>1265</lpage><pub-id pub-id-type="pmid">12029140</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>SA</given-names></name><name><surname>Sackett</surname><given-names>K</given-names></name><name><surname>Rawat</surname><given-names>SS</given-names></name><name><surname>Shai</surname><given-names>Y</given-names></name><name><surname>Blumenthal</surname><given-names>R</given-names></name></person-group><article-title>The Stability of the Intact Envelope Glycoproteins is a Major Determinant of Sensitivity of HIV/SIV to Peptidic Fusion Inhibitors</article-title><source>J Mol Biol</source><year>2004</year><volume>340</volume><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15184018</pub-id><pub-id pub-id-type="doi">10.1016/j.jmb.2004.04.027</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blumenthal</surname><given-names>R</given-names></name><name><surname>Clague</surname><given-names>MJ</given-names></name><name><surname>Durell</surname><given-names>SR</given-names></name><name><surname>Epand</surname><given-names>RM</given-names></name></person-group><article-title>Membrane fusion</article-title><source>Chem Rev</source><year>2003</year><volume>103</volume><fpage>53</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">12517181</pub-id><pub-id pub-id-type="doi">10.1021/cr000036+</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gustchina</surname><given-names>E</given-names></name><name><surname>Hummer</surname><given-names>G</given-names></name><name><surname>Bewley</surname><given-names>CA</given-names></name><name><surname>Clore</surname><given-names>GM</given-names></name></person-group><article-title>Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV</article-title><source>J Med Chem</source><year>2005</year><volume>48</volume><fpage>3036</fpage><lpage>3044</lpage><pub-id pub-id-type="pmid">15828842</pub-id><pub-id pub-id-type="doi">10.1021/jm049026h</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jernigan</surname><given-names>KM</given-names></name><name><surname>Blumenthal</surname><given-names>R</given-names></name><name><surname>Puri</surname><given-names>A</given-names></name></person-group><article-title>Varying effects of temperature, Ca(2+) and cytochalasin on fusion activity mediated by human immunodeficiency virus type 1 and type 2 glycoproteins</article-title><source>FEBS Lett</source><year>2000</year><volume>474</volume><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">10838094</pub-id><pub-id pub-id-type="doi">10.1016/S0014-5793(00)01600-8</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Puri</surname><given-names>A</given-names></name><name><surname>Hug</surname><given-names>P</given-names></name><name><surname>Munoz-Barroso</surname><given-names>I</given-names></name><name><surname>Blumenthal</surname><given-names>R</given-names></name></person-group><article-title>Human erythrocyte glycolipids promote HIV-1 envelope glycoprotein-mediated fusion of CD4+ cells</article-title><source>Biochem Biophys Res Commun</source><year>1998</year><volume>242</volume><fpage>219</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">9439639</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1997.7941</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>SA</given-names></name><name><surname>Finnegan</surname><given-names>CM</given-names></name><name><surname>Viard</surname><given-names>M</given-names></name><name><surname>Raviv</surname><given-names>Y</given-names></name><name><surname>Dimitrov</surname><given-names>A</given-names></name><name><surname>Rawat</surname><given-names>SS</given-names></name><name><surname>Puri</surname><given-names>A</given-names></name><name><surname>Durell</surname><given-names>S</given-names></name><name><surname>Blumenthal</surname><given-names>R</given-names></name></person-group><article-title>The HIV Env-mediated fusion reaction</article-title><source>Biochim Biophys Acta</source><year>2003</year><volume>1614</volume><fpage>36</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">12873764</pub-id><pub-id pub-id-type="doi">10.1016/S0005-2736(03)00161-5</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>JD</given-names></name><name><surname>Gallo</surname><given-names>SA</given-names></name><name><surname>Ahmad</surname><given-names>N</given-names></name><name><surname>Miamidian</surname><given-names>JL</given-names></name><name><surname>Harvey</surname><given-names>PE</given-names></name><name><surname>Sharron</surname><given-names>M</given-names></name><name><surname>Pohlmann</surname><given-names>S</given-names></name><name><surname>Sfakianos</surname><given-names>JN</given-names></name><name><surname>Derdeyn</surname><given-names>CA</given-names></name><name><surname>Blumenthal</surname><given-names>R</given-names></name><name><surname>Hunter</surname><given-names>E</given-names></name><name><surname>Doms</surname><given-names>RW</given-names></name></person-group><article-title>Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><fpage>16249</fpage><lpage>16254</lpage><pub-id pub-id-type="pmid">12444251</pub-id><pub-id pub-id-type="doi">10.1073/pnas.252469399</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>JD</given-names></name><name><surname>Miamidian</surname><given-names>JL</given-names></name><name><surname>Biscone</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>FH</given-names></name><name><surname>Ahmad</surname><given-names>N</given-names></name><name><surname>Pierson</surname><given-names>TC</given-names></name><name><surname>Doms</surname><given-names>RW</given-names></name></person-group><article-title>Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>5476</fpage><lpage>5485</lpage><pub-id pub-id-type="pmid">15113926</pub-id><pub-id pub-id-type="doi">10.1128/JVI.78.10.5476-5485.2004</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallo</surname><given-names>SA</given-names></name><name><surname>Puri</surname><given-names>A</given-names></name><name><surname>Blumenthal</surname><given-names>R</given-names></name></person-group><article-title>HIV-1 gp41 Six-Helix Bundle Formation Occurs Rapidly after the Engagement of gp120 by CXCR4 in the HIV-1 Env-Mediated Fusion Process</article-title><source>Biochemistry</source><year>2001</year><volume>40</volume><fpage>12231</fpage><lpage>12236</lpage><pub-id pub-id-type="pmid">11591141</pub-id><pub-id pub-id-type="doi">10.1021/bi0155596</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>DC</given-names></name><name><surname>Kim</surname><given-names>PS</given-names></name></person-group><article-title>HIV entry and its inhibition</article-title><source>Cell</source><year>1998</year><volume>93</volume><fpage>681</fpage><lpage>684</lpage><pub-id pub-id-type="pmid">9630213</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81430-0</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>RA</given-names></name><name><surname>Wild</surname><given-names>CT</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><name><surname>Weiss</surname><given-names>CD</given-names></name></person-group><article-title>Capture of an early fusion-active conformation of HIV-1 gp41</article-title><source>Nat Struct Biol</source><year>1998</year><volume>5</volume><fpage>276</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">9546217</pub-id><pub-id pub-id-type="doi">10.1038/nsb0498-276</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weissenhorn</surname><given-names>W</given-names></name><name><surname>Dessen</surname><given-names>A</given-names></name><name><surname>Calder</surname><given-names>LJ</given-names></name><name><surname>Harrison</surname><given-names>SC</given-names></name><name><surname>Skehel</surname><given-names>JJ</given-names></name><name><surname>Wiley</surname><given-names>DC</given-names></name></person-group><article-title>Structural basis for membrane fusion by enveloped viruses</article-title><source>Mol Membr Biol</source><year>1999</year><volume>16</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10332732</pub-id><pub-id pub-id-type="doi">10.1080/096876899294706</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Doms</surname><given-names>RW</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name></person-group><article-title>HIV-1 membrane fusion: targets of opportunity</article-title><source>J Cell Biol</source><year>2000</year><volume>151</volume><fpage>F9</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">11038194</pub-id><pub-id pub-id-type="doi">10.1083/jcb.151.2.F9</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sodroski</surname><given-names>JG</given-names></name></person-group><article-title>HIV-1 entry inhibitors in the side pocket</article-title><source>Cell</source><year>1999</year><volume>99</volume><fpage>243</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">10555140</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81655-4</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melikyan</surname><given-names>GB</given-names></name><name><surname>Markosyan</surname><given-names>RM</given-names></name><name><surname>Hemmati</surname><given-names>H</given-names></name><name><surname>Delmedico</surname><given-names>MK</given-names></name><name><surname>Lambert</surname><given-names>DM</given-names></name><name><surname>Cohen</surname><given-names>FS</given-names></name></person-group><article-title>Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion</article-title><source>J Cell Biol</source><year>2000</year><volume>151</volume><fpage>413</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">11038187</pub-id><pub-id pub-id-type="doi">10.1083/jcb.151.2.413</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Munoz-Barroso</surname><given-names>I</given-names></name><name><surname>Durell</surname><given-names>S</given-names></name><name><surname>Sakaguchi</surname><given-names>K</given-names></name><name><surname>Appella</surname><given-names>E</given-names></name><name><surname>Blumenthal</surname><given-names>R</given-names></name></person-group><article-title>Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41</article-title><source>J Cell Biol</source><year>1998</year><volume>140</volume><fpage>315</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">9442107</pub-id><pub-id pub-id-type="doi">10.1083/jcb.140.2.315</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salzwedel</surname><given-names>K</given-names></name><name><surname>Berger</surname><given-names>EA</given-names></name></person-group><article-title>Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: Functional complementation of specific defects in gp120 and gp41</article-title><source>Proceedings of the National Academy of Sciences</source><year>2000</year><volume>97</volume><fpage>12794</fpage><lpage>12799</lpage><pub-id pub-id-type="doi">10.1073/pnas.230438497</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wyss</surname><given-names>S</given-names></name><name><surname>Dimitrov</surname><given-names>AS</given-names></name><name><surname>Baribaud</surname><given-names>F</given-names></name><name><surname>Edwards</surname><given-names>TG</given-names></name><name><surname>Blumenthal</surname><given-names>R</given-names></name><name><surname>Hoxie</surname><given-names>JA</given-names></name></person-group><article-title>Regulation of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion by a Membrane-Interactive Domain in the gp41 Cytoplasmic Tail</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>12231</fpage><lpage>12241</lpage><pub-id pub-id-type="pmid">16160149</pub-id><pub-id pub-id-type="doi">10.1128/JVI.79.19.12231-12241.2005</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JT</given-names></name><name><surname>Kim</surname><given-names>EM</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Choi</surname><given-names>JE</given-names></name><name><surname>Jhun</surname><given-names>BH</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name></person-group><article-title>Leucine zipper domain of HIV-1 gp41 interacted specifically with alpha-catenin</article-title><source>Biochem Biophys Res Commun</source><year>2002</year><volume>291</volume><fpage>1239</fpage><lpage>1244</lpage><pub-id pub-id-type="pmid">11883950</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.2002.6583</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tencza</surname><given-names>SB</given-names></name><name><surname>Miller</surname><given-names>MA</given-names></name><name><surname>Islam</surname><given-names>K</given-names></name><name><surname>Mietzner</surname><given-names>TA</given-names></name><name><surname>Montelaro</surname><given-names>RC</given-names></name></person-group><article-title>Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein</article-title><source>J Virol</source><year>1995</year><volume>69</volume><fpage>5199</fpage><lpage>5202</lpage><pub-id pub-id-type="pmid">7609094</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kao</surname><given-names>S</given-names></name><name><surname>Whitehead</surname><given-names>IP</given-names></name><name><surname>Hart</surname><given-names>MJ</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Duus</surname><given-names>K</given-names></name><name><surname>Burridge</surname><given-names>K</given-names></name><name><surname>Der</surname><given-names>CJ</given-names></name><name><surname>Su</surname><given-names>L</given-names></name></person-group><article-title>Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF</article-title><source>Curr Biol</source><year>1999</year><volume>9</volume><fpage>1271</fpage><lpage>1274</lpage><pub-id pub-id-type="pmid">10556093</pub-id><pub-id pub-id-type="doi">10.1016/S0960-9822(99)80511-9</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>DT</given-names></name><name><surname>Tillman</surname><given-names>KC</given-names></name><name><surname>Desrosiers</surname><given-names>RC</given-names></name></person-group><article-title>Envelope glycoprotein cytoplasmic domains from diverse lentiviruses interact with the prenylated Rab acceptor</article-title><source>J Virol</source><year>2002</year><volume>76</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">11739697</pub-id><pub-id pub-id-type="doi">10.1128/JVI.76.1.327-337.2002</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wyss</surname><given-names>S</given-names></name><name><surname>Berlioz-Torrent</surname><given-names>C</given-names></name><name><surname>Boge</surname><given-names>M</given-names></name><name><surname>Blot</surname><given-names>G</given-names></name><name><surname>Honing</surname><given-names>S</given-names></name><name><surname>Benarous</surname><given-names>R</given-names></name><name><surname>Thali</surname><given-names>M</given-names></name></person-group><article-title>The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter]</article-title><source>J Virol</source><year>2001</year><volume>75</volume><fpage>2982</fpage><lpage>2992</lpage><pub-id pub-id-type="pmid">11222723</pub-id><pub-id pub-id-type="doi">10.1128/JVI.75.6.2982-2992.2001</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MA</given-names></name><name><surname>Cloyd</surname><given-names>MW</given-names></name><name><surname>Liebmann</surname><given-names>J</given-names></name><name><surname>Rinaldo</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Islam</surname><given-names>KR</given-names></name><name><surname>Wang</surname><given-names>SZ</given-names></name><name><surname>Mietzner</surname><given-names>TA</given-names></name><name><surname>Montelaro</surname><given-names>RC</given-names></name></person-group><article-title>Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein</article-title><source>Virology</source><year>1993</year><volume>196</volume><fpage>89</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">8356808</pub-id><pub-id pub-id-type="doi">10.1006/viro.1993.1457</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kliger</surname><given-names>Y</given-names></name><name><surname>Shai</surname><given-names>Y</given-names></name></person-group><article-title>A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers</article-title><source>Biochemistry</source><year>1997</year><volume>36</volume><fpage>5157</fpage><lpage>5169</lpage><pub-id pub-id-type="pmid">9136877</pub-id><pub-id pub-id-type="doi">10.1021/bi962935r</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Comardelle</surname><given-names>AM</given-names></name><name><surname>Norris</surname><given-names>CH</given-names></name><name><surname>Plymale</surname><given-names>DR</given-names></name><name><surname>Gatti</surname><given-names>PJ</given-names></name><name><surname>Choi</surname><given-names>B</given-names></name><name><surname>Fermin</surname><given-names>CD</given-names></name><name><surname>Haislip</surname><given-names>AM</given-names></name><name><surname>Tencza</surname><given-names>SB</given-names></name><name><surname>Mietzner</surname><given-names>TA</given-names></name><name><surname>Montelaro</surname><given-names>RC</given-names></name><name><surname>Garry</surname><given-names>RF</given-names></name></person-group><article-title>A synthetic peptide corresponding to the carboxy terminus of human immunodeficiency virus type 1 transmembrane glycoprotein induces alterations in the ionic permeability of Xenopus laevis oocytes</article-title><source>AIDS Res Hum Retroviruses</source><year>1997</year><volume>%20;13</volume><fpage>1525</fpage><lpage>1532</lpage><pub-id pub-id-type="pmid">9390752</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freed</surname><given-names>EO</given-names></name><name><surname>Martin</surname><given-names>MA</given-names></name></person-group><article-title>Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions</article-title><source>J Virol</source><year>1996</year><volume>70</volume><fpage>341</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">8523546</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wyma</surname><given-names>DJ</given-names></name><name><surname>Kotov</surname><given-names>A</given-names></name><name><surname>Aiken</surname><given-names>C</given-names></name></person-group><article-title>Evidence for a stable interaction of gp41 with Pr55(Gag) in immature human immunodeficiency virus type 1 particles</article-title><source>J Virol</source><year>2000</year><volume>74</volume><fpage>9381</fpage><lpage>9387</lpage><pub-id pub-id-type="pmid">11000206</pub-id><pub-id pub-id-type="doi">10.1128/JVI.74.20.9381-9387.2000</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wyma</surname><given-names>DJ</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Lineberger</surname><given-names>JE</given-names></name><name><surname>Miller</surname><given-names>MD</given-names></name><name><surname>Aiken</surname><given-names>C</given-names></name></person-group><article-title>Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>3429</fpage><lpage>3435</lpage><pub-id pub-id-type="pmid">15016865</pub-id><pub-id pub-id-type="doi">10.1128/JVI.78.7.3429-3435.2004</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>T</given-names></name><name><surname>Ablan</surname><given-names>S</given-names></name><name><surname>Freed</surname><given-names>EO</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name></person-group><article-title>Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>1026</fpage><lpage>1031</lpage><pub-id pub-id-type="pmid">14694135</pub-id><pub-id pub-id-type="doi">10.1128/JVI.78.2.1026-1031.2004</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abrahamyan</surname><given-names>LG</given-names></name><name><surname>Mkrtchyan</surname><given-names>SR</given-names></name><name><surname>Binley</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Melikyan</surname><given-names>GB</given-names></name><name><surname>Cohen</surname><given-names>FS</given-names></name></person-group><article-title>The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle</article-title><source>J Virol</source><year>2005</year><volume>79</volume><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">15596806</pub-id><pub-id pub-id-type="doi">10.1128/JVI.79.1.106-115.2005</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>TG</given-names></name><name><surname>Wyss</surname><given-names>S</given-names></name><name><surname>Reeves</surname><given-names>JD</given-names></name><name><surname>Zolla-Pazner</surname><given-names>S</given-names></name><name><surname>Hoxie</surname><given-names>JA</given-names></name><name><surname>Doms</surname><given-names>RW</given-names></name><name><surname>Baribaud</surname><given-names>F</given-names></name></person-group><article-title>Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein</article-title><source>J Virol</source><year>2002</year><volume>76</volume><fpage>2683</fpage><lpage>2691</lpage><pub-id pub-id-type="pmid">11861835</pub-id><pub-id pub-id-type="doi">10.1128/JVI.76.6.2683-2691.2002</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schols</surname><given-names>D</given-names></name><name><surname>Struyf</surname><given-names>S</given-names></name><name><surname>Van Damme</surname><given-names>J</given-names></name><name><surname>Este</surname><given-names>JA</given-names></name><name><surname>Henson</surname><given-names>G</given-names></name><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group><article-title>Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4</article-title><source>J Exp Med</source><year>1997</year><volume>186</volume><fpage>1383</fpage><lpage>1388</lpage><pub-id pub-id-type="pmid">9334378</pub-id><pub-id pub-id-type="doi">10.1084/jem.186.8.1383</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sattentau</surname><given-names>QJ</given-names></name><name><surname>Dalgleish</surname><given-names>AG</given-names></name><name><surname>Weiss</surname><given-names>RA</given-names></name><name><surname>Beverley</surname><given-names>PC</given-names></name></person-group><article-title>Epitopes of the CD4 antigen and HIV infection</article-title><source>Science</source><year>1986</year><volume>234</volume><fpage>1120</fpage><lpage>1123</lpage><pub-id pub-id-type="pmid">2430333</pub-id><pub-id pub-id-type="doi">10.1126/science.2430333</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>TL</given-names></name><name><surname>LaBranche</surname><given-names>CC</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Canziani</surname><given-names>G</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Chaiken</surname><given-names>I</given-names></name><name><surname>Hoxie</surname><given-names>JA</given-names></name><name><surname>Doms</surname><given-names>RW</given-names></name></person-group><article-title>Stable exposure of the coreceptor-binding site in a CD4-independent HIV- 1 envelope protein</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>6359</fpage><lpage>6364</lpage><pub-id pub-id-type="pmid">10339592</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.11.6359</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>G</given-names></name><name><surname>Baribaud</surname><given-names>F</given-names></name><name><surname>Romano</surname><given-names>J</given-names></name><name><surname>Doms</surname><given-names>RW</given-names></name><name><surname>Hoxie</surname><given-names>JA</given-names></name></person-group><article-title>Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins</article-title><source>J Virol</source><year>2003</year><volume>77</volume><fpage>931</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">12502809</pub-id><pub-id pub-id-type="doi">10.1128/JVI.77.2.931-942.2003</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Earl</surname><given-names>PL</given-names></name><name><surname>Koenig</surname><given-names>S</given-names></name><name><surname>Moss</surname><given-names>B</given-names></name></person-group><article-title>Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses</article-title><source>J Virol</source><year>1991</year><volume>65</volume><fpage>31</fpage><lpage>41.</lpage><pub-id pub-id-type="pmid">1985202</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mulligan</surname><given-names>MJ</given-names></name><name><surname>Ritter</surname><given-names>GD</given-names><suffix>Jr</suffix></name><name><surname>Chaikin</surname><given-names>MA</given-names></name><name><surname>Yamshchikov</surname><given-names>GV</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Sweet</surname><given-names>RW</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name></person-group><article-title>Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex</article-title><source>Virology</source><year>1992</year><volume>187</volume><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">1736526</pub-id><pub-id pub-id-type="doi">10.1016/0042-6822(92)90311-C</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chakrabarti</surname><given-names>S</given-names></name><name><surname>Mizukami</surname><given-names>T</given-names></name><name><surname>Franchini</surname><given-names>G</given-names></name><name><surname>Moss</surname><given-names>B</given-names></name></person-group><article-title>Synthesis, oligomerization, and biological activity of the human immunodeficiency virus type 2 envelope glycoprotein expressed by a recombinant vaccinia virus</article-title><source>Virology</source><year>1990</year><volume>178</volume><fpage>134</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">2117828</pub-id><pub-id pub-id-type="doi">10.1016/0042-6822(90)90386-6</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reeves</surname><given-names>JD</given-names></name><name><surname>Schulz</surname><given-names>TF</given-names></name></person-group><article-title>The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion</article-title><source>J Virol</source><year>1997</year><volume>71</volume><fpage>1453</fpage><lpage>1465</lpage><pub-id pub-id-type="pmid">8995671</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Edinger</surname><given-names>AL</given-names></name><name><surname>Blanpain</surname><given-names>C</given-names></name><name><surname>Kunstman</surname><given-names>KJ</given-names></name><name><surname>Wolinsky</surname><given-names>SM</given-names></name><name><surname>Parmentier</surname><given-names>M</given-names></name><name><surname>Doms</surname><given-names>RW</given-names></name></person-group><article-title>Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains</article-title><source>J Virol</source><year>1999</year><volume>73</volume><fpage>4062</fpage><lpage>4073</lpage><pub-id pub-id-type="pmid">10196302</pub-id></citation></ref></ref-list></back></article> 